Di Huang

Di Huang

Auto-generated profile, based on publicly available information

Di Huang

Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
DHDi Huang
Di Huang
YCYing-Shan Chen
Ying-Shan Chen
Ilva RupenthalIlva Rupenthal
Ilva Rupenthal

1 April 2015 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
YDYixuan Dong
Yixuan Dong
PDPin Dong
Pin Dong
DHDi Huang
Di Huang
LMLiling Mei
Liling Mei
YXYaowen Xia
Yaowen Xia
Chuanbin WuChuanbin Wu
Chuanbin Wu

10 January 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DHDi Huang
Di Huang
YCYing-Shan Chen
Ying-Shan Chen
Ilva RupenthalIlva Rupenthal
Ilva Rupenthal

6 December 2022 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DHDi Huang
Di Huang
MTMaie S. Taha
Maie S. Taha
ANAngela L. Nocera
Angela L. Nocera
AWAlan D. Workman
Alan D. Workman
Mansoor M. AmijiMansoor M. Amiji
Mansoor M. Amiji
BBBenjamin S. Bleier
Benjamin S. Bleier

1 June 2018 in Biomaterials
Verified
Journal Article
Closed access
DHDi Huang
Di Huang
YCYing-Shan Chen
Ying-Shan Chen
CGColin R. Green
Colin R. Green
Ilva RupenthalIlva Rupenthal
Ilva Rupenthal

31 October 2022 in Bioactive Materials
Verified
Journal Article
Open access
KSKanika Suri
Kanika Suri
ADAnisha D'SOuza
Anisha D'SOuza
DHDi Huang
Di Huang
ABAashray Bhavsar
Aashray Bhavsar
Mansoor M. AmijiMansoor M. Amiji
Mansoor M. Amiji
Cancer therapy is undergoing a paradigm shift toward immunotherapy focusing on various approaches to activate the host immune system. As research to identify appropriate immune cells and activate anti-tumor immunity continues to expand, scientists are looking at microbial sources given their inherent ability to elicit an immune response. Bacterial extracellular vesicles (BEVs) are actively studied to control systemic humoral and cellular immune responses instead of using whole microorganisms or other types of extracellular vesicles (EVs). BEVs also provide the opportunity as versatile drug delivery carriers. Unlike mammalian EVs, BEVs have already made it to the clinic with the meningococcal vaccine (Bexsero®). However, there are still many unanswered questions in the use of BEVs, especially for chronic systemically administered immunotherapies. In this review, we address the opportunities and challenges in the use of BEVs for cancer immunotherapy and provide an outlook towards development of BEV products that can ultimately translate to the clinic.